Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: margie who wrote (5543)	10/20/1998 4:06:00 PM
From: Steve Fancy	Read Replies (1) \| Respond to of 6136

.21 share fully diluted. sf

To: margie who wrote (5543)	10/20/1998 8:26:00 PM
From: M. Alexander	Read Replies (1) \| Respond to of 6136

This is for Margie so hold your temper Richard. Margie, as far as McCamant's concern there is no concern. He loves AGPH. I was simply answering my own "butted in" question about 4Q98 earnings. But call me a short anyway. It won't influence the stock price no matter what we say I'm sure. M. Alexander

To: margie who wrote (5543)	10/21/1998 1:42:00 PM
From: John Romeo	Respond to of 6136

I had the opportunity to participate in what I felt was an excellent conference call last night. In respect to Ritonavir, AGPH mgt guided us to 65% on liquid and 35% on remaining on capsule. Of interest mgt. would not forecast any market share gain in it's guidance, or loss on Abbot's side. A price increase of 4.6% on Viracept effective October 1st has held up and 150,000 are now using the drug worlwide.Market share is 40% vs.39% for Crixivan.Doug Lind of Morgan Stanley, a onetime bull when he was at PaineWebber, asked if lipodystrophy or Crix Belly was showing up in any frequency. Management qouted the 511 study which is continuing now over 70 weeks had shown little indications of this side effect. Viracept continues to be a very safe and potent protease inhibitor justifying it's current market share, in my opinion. Steve Cowell,CFO guided to FY99 total U.S. Viracept sales of $430-440million. One concern was the mention of contractual payments due IMNR and/or others in Q3 99 could put earnings into the red for that qtr.So, going forward, accurate eps estimates may be more difficult or less reliable. I've got more but I have said enough. John L. R.